Department of Experimental Medicine, Imperial College, Burlington Danes Building, Hammersmith Hospital Site, 160 Du Cane Road, London, UK.
Br Med Bull. 2010;96:93-110. doi: 10.1093/bmb/ldq032. Epub 2010 Nov 2.
Our knowledge about the neuropharmacology of addiction is increasing and is leading to more informed development of pharmacotherapy. Although the dopaminergic mesolimbic system plays a central role in 'liking', reward and motivation, medications directly targeting it have not proved a very fruitful approach to treating addictions. A review of the literature was performed to find articles relating current and developing pharmacological treatments in the clinic and their underlying neuropharmacology. We focussed on the most common addictions for which pharmacology plays an important role. By characterizing what neurotransmitters modulate this dopaminergic pathway, new medications are now in the clinic and being successfully applied to treat a variety of addictions. In addition to modulating this reward pathway, alternative approaches in the future will target learning and memory, improving impulse control and decision-making.
我们对成瘾的神经药理学的认识正在不断增加,并正在导致更有针对性地开发药物治疗。尽管多巴胺能中脑边缘系统在“喜欢”、奖励和动机中起着核心作用,但直接针对它的药物治疗并没有证明是治疗成瘾的一种非常有效的方法。我们对文献进行了回顾,以寻找与临床中当前和正在开发的药理学治疗及其潜在神经药理学相关的文章。我们专注于药理学起着重要作用的最常见的成瘾。通过描述哪些神经递质调节这种多巴胺能途径,新的药物现在已经在临床上,并成功地应用于治疗各种成瘾。除了调节这条奖励途径外,未来的替代方法还将针对学习和记忆,改善冲动控制和决策。